#1 Clinical Trials Search in Europe

Ralinepag

Ralinepag is an investigational drug being studied in clinical trials for the treatment of pulmonary arterial hypertension (PAH). PAH is a rare but serious condition characterized by high blood pressure in the arteries of the lungs. This article summarizes key information from several clinical trials evaluating the safety, efficacy, and long-term effects of ralinepag in patients with PAH.

Table of Contents

What is Ralinepag?

Ralinepag, also known as APD811, is a new medication being developed to treat pulmonary arterial hypertension (PAH)[1]. It is currently undergoing clinical trials to evaluate its effectiveness and safety in patients with this serious condition. Ralinepag is designed to be a long-acting drug that can be taken orally once daily, which could make it more convenient for patients compared to some existing treatments[2].

What Conditions Does Ralinepag Treat?

Ralinepag is primarily being studied for the treatment of pulmonary arterial hypertension (PAH). PAH is a rare but serious condition where the blood pressure in the arteries of the lungs becomes abnormally high. This puts strain on the heart and can lead to symptoms such as shortness of breath, fatigue, and chest pain[1]. Some specific types of PAH that Ralinepag may help with include:

  • World Health Organization (WHO) Group 1 PAH
  • PAH associated with connective tissue diseases
  • Familial (inherited) PAH
These conditions are all characterized by high blood pressure in the lungs, which Ralinepag aims to address[2].

How Does Ralinepag Work?

Ralinepag belongs to a class of drugs called prostacyclin receptor agonists. It works by mimicking the effects of a natural substance in the body called prostacyclin. Prostacyclin helps to relax and widen blood vessels, which can lower blood pressure in the lungs and improve blood flow. By activating prostacyclin receptors, Ralinepag may help to:

  • Reduce blood pressure in the pulmonary arteries
  • Improve blood flow through the lungs
  • Decrease the workload on the heart
  • Potentially slow down the progression of PAH
These effects could lead to improvements in symptoms and overall quality of life for patients with PAH[1][2].

How is Ralinepag Administered?

Ralinepag is being developed as an oral medication, which means it can be taken by mouth. It comes in the form of extended-release (XR) tablets. The dosage being studied includes:

  • 50 mcg tablets
  • 250 mcg tablets
  • 400 mcg tablets
In clinical trials, patients typically start with a lower dose and gradually increase to the highest tolerated dose. This process is called dose titration. The maximum dose being studied is 1400 mcg once daily[2][1].

Ongoing Clinical Trials

Ralinepag is currently being studied in several clinical trials to evaluate its effectiveness and safety. Some of the key trials include:

  • ADVANCE OUTCOMES (NCT03626688): This is a Phase 3 study looking at how well Ralinepag works when added to standard PAH treatments. It’s measuring how long it takes for patients’ conditions to worsen[1].
  • ADVANCE CAPACITY (NCT04084678): Another Phase 3 study focusing on how Ralinepag affects exercise capacity in PAH patients. It’s measuring changes in peak oxygen consumption during exercise[2].
  • Long-term Extension Studies: There are also studies looking at the long-term safety and effectiveness of Ralinepag in patients who have completed earlier trials[3][4].
These trials are helping researchers understand how well Ralinepag works and how safe it is for long-term use in PAH patients.

Safety and Side Effects

As with any medication, safety is a crucial aspect of Ralinepag’s development. The clinical trials are closely monitoring for any side effects or adverse events. Some of the things being assessed include:

  • Changes in vital signs (like heart rate and blood pressure)
  • Blood tests to check liver and kidney function
  • Effects on the heart (through ECG measurements)
  • Any unexpected side effects or reactions
It’s important to note that the full safety profile of Ralinepag is still being determined through these ongoing studies[5][1].

Future Prospects for Ralinepag

If the clinical trials show positive results, Ralinepag could become a valuable new treatment option for patients with PAH. Some potential advantages of Ralinepag include:

  • Once-daily oral dosing, which could be more convenient than some existing treatments
  • Potential to improve exercise capacity and quality of life
  • Possibility of slowing disease progression
However, it’s important to remember that Ralinepag is still an investigational drug. It will need to complete all phases of clinical trials and receive approval from regulatory agencies before it can be made available to patients outside of clinical studies[1][2].

Aspect Details
Drug Name Ralinepag (also known as APD811)
Condition Studied Pulmonary Arterial Hypertension (PAH)
Trial Phases Phase 1, 2, and 3
Administration Oral extended-release tablets, once daily
Dosage Range 50-1400 mcg, titrated to maximum tolerated dose
Key Outcome Measures Exercise capacity (6MWD, CPET), NT-proBNP levels, WHO Functional Class, quality of life, time to clinical worsening
Safety Monitoring Adverse events, vital signs, laboratory tests, ECG
Study Designs Randomized, placebo-controlled, open-label extension
Study Durations Range from 28 weeks to several years for long-term follow-up
Patient Populations Healthy volunteers (Phase 1), PAH patients (Phase 2/3)

FAQ

  • What is ralinepag? Ralinepag is an investigational drug being studied as a potential treatment for pulmonary arterial hypertension (PAH). It is taken orally as extended-release tablets and works to help improve blood flow in the lungs.
  • What types of clinical trials are being conducted with ralinepag? Several types of clinical trials are evaluating ralinepag, including Phase 1 studies in healthy volunteers to assess safety and pharmacokinetics, as well as Phase 2 and 3 studies in PAH patients to evaluate its efficacy, safety, and long-term effects when added to standard PAH treatments.
  • What are some of the main outcomes being measured in ralinepag clinical trials? Key outcomes being measured include changes in exercise capacity (e.g. 6-minute walk distance), pulmonary vascular resistance, NT-proBNP levels (a marker of heart stress), WHO functional class, quality of life, and time to clinical worsening events like hospitalization.
  • How is ralinepag administered in the clinical trials? Ralinepag is given as oral extended-release tablets, usually once daily. The dosage is typically titrated up over time to reach the maximum tolerated dose for each individual patient, with doses ranging from 50-1400 mcg per day in the trials.
  • Are there any known side effects of ralinepag from the clinical trials? While full safety data is still being collected, common side effects of prostacyclin-type medications like ralinepag can include headache, nausea, diarrhea, jaw pain, and flushing. The clinical trials are carefully monitoring all adverse events to establish the safety profile.

Ongoing Clinical Trials on Ralinepag

  • Study on the Effectiveness and Safety of Ralinepag for Patients with Pulmonary Arterial Hypertension

    Not recruiting

    1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +9

  • Study on the Long-term Safety and Efficacy of Ralinepag for Patients with Pulmonary Arterial Hypertension

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Czechia Denmark France +9

Glossary

  • Pulmonary Arterial Hypertension (PAH): A rare but serious condition characterized by high blood pressure in the arteries of the lungs, which can lead to heart failure if left untreated.
  • 6-Minute Walk Distance (6MWD): A test that measures the distance a patient can walk in 6 minutes, used to assess exercise capacity and disease progression in PAH.
  • NT-proBNP: N-terminal pro-brain natriuretic peptide, a blood marker that indicates stress on the heart. Elevated levels can indicate worsening PAH.
  • WHO Functional Class: A system used to classify the severity of symptoms in PAH patients, ranging from Class I (no symptoms) to Class IV (severe limitations).
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Open-Label Extension (OLE): A type of clinical trial where all participants receive the active drug, often following a placebo-controlled study, to gather long-term safety and efficacy data.
  • Clinical Worsening: In PAH trials, this often refers to events like death, hospitalization for worsening PAH, need for additional PAH therapies, or significant decline in functional capacity.
  • Cardiopulmonary Exercise Testing (CPET): A comprehensive test that measures heart, lung, and muscle function during exercise, used to assess exercise capacity in PAH patients.
  • Peak VO2: The maximum rate of oxygen consumption measured during incremental exercise, a key measure of cardiorespiratory fitness assessed by CPET.
  • Pulmonary Vascular Resistance (PVR): A measure of the resistance to blood flow in the pulmonary arteries, which is typically elevated in PAH patients.

References